Lithium gamolenate

Drug Profile

Lithium gamolenate

Alternative Names: EF 13; Glamolec; LiGLA; Lithium-gamma linolenate; Lithium-GLA

Latest Information Update: 25 Jul 2000

Price : $50

At a glance

  • Originator Scotia Pharmaceuticals [CEASED]
  • Class Antineoplastics; Small molecules; Unsaturated fatty acids
  • Mechanism of Action Prostaglandin synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Glioma; HIV infections; Lung cancer; Pancreatic cancer

Most Recent Events

  • 25 Jul 2000 Discontinued-II for Colorectal cancer in United Kingdom (Unknown route)
  • 28 Apr 1999 Discontinued-III for Pancreatic cancer in Australia (IV)
  • 28 Apr 1999 Discontinued-III for Pancreatic cancer in New Zealand (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top